GZYK(002524)2024-07-10 11:17Financial Performance - The estimated net profit attributable to shareholders for the first half of 2024 is projected to be between 1 million and 1.5 million yuan, representing a decline of 71.00% to 80.67% compared to the same period last year, which was 5.1722 million yuan [3]. - The net profit after deducting non-recurring gains and losses is expected to be between -7.5 million and -6.5 million yuan, a decrease of 259.37% to 283.89% from 4.0785 million yuan in the previous year [3]. - Basic earnings per share are projected to be between 0.00 yuan and 0.00 yuan, down from 0.01 yuan in the same period last year [3]. Revenue Performance - The company's ophthalmology business revenue remained stable compared to the previous year, while the steel structure segment's revenue fell short of expectations due to external economic conditions, leading to a slight overall decrease in revenue [5]. Cost and Expenses - Increased sales expenses and higher stock incentive costs from a new round of equity incentives implemented in 2023 contributed to the decline in net profit compared to the previous year [5]. Financial Reporting - The financial data presented is based on preliminary estimates by the company's finance department and has not been audited by an accounting firm [4]. - Investors are advised to make cautious decisions and be aware of investment risks as the final financial data will be disclosed in the company's 2024 semi-annual report [6].